103
Id., slip op. at 48 (opinion of the Commission). The Commission previously had
recognized support in the case law for the misrepresentation exception to Noerr in connection
with the allegedly anticompetitive activities of Bristol-Myers Squibb discussed above. See
Memorandum of Law of Amicus Curiae the Federal Trade Commission in Opposition to
Defendant’s Motion to Dismiss at 21, In re Buspirone, MDL No. 1410 (JGK) (S.D.N.Y. Jan. 8,
2002), available at http://www.ftc.gov/os/2002/01/busparbrief.pdf (“[M]any courts have held
that Noerr immunity does not extend to knowing and material misrepresentations made in
adjudicatory or administrative proceedings.”). See also Bristol-Myers Squibb Co., FTC Dkt. No.
C-4076 (2003) (analysis to aid public comment), available at
http://www.ftc.gov/os/2003/03/bristolmyersanalysis.htm (“BMS’s filings and other statements to
the FDA are alleged to involve knowing and material misrepresentations, and would therefore
fall outside the protection of the Noerr doctrine for that reason as well.”).
104
Unocal, slip op. at 16-17 (citing, among others, Whelan, 48 F.3d 1247 (D.C. Cir.
1995); Juster Assocs. v. City of Rutland, Vt., 901 F.2d 266 (2d Cir. 1990); Woods Exploration &
Producing Co. v. Aluminum Co. of Am., 438 F.2d 1286 (5th Cir. 1971); Potters Med. Ctr. v. City
Hosp. Ass’n, 800 F.2d 568 (6th Cir. 1986); Metro Cable Co. v. CATV of Rockford, Inc., 516 F.2d
220 (7th Cir. 1975); Porous Media Corp. v. Pall Corp., 186 F.3d 1077 (8th Cir. 1999); Kottle v.
Nw. Kidney Ctrs., 146 F.3d 1056 (9th Cir. 1998); St. Joseph’s Hosp., Inc. v. Hosp. Corp. of Am.,
795 F.2d 948 (11th Cir. 1986); Rodime PLC v. Seagate Tech., Inc., 174 F.3d 1294 (Fed. Cir.
1999)). The Commission further noted that, although the Third Circuit has expressed skepticism
regarding, and the Fourth Circuit has declined to rule on the existence of, the misrepresentation
exception, the relevant decisions of those two circuits are not necessarily inconsistent with the
Commission’s conclusion that such an exception exists. See Unocal, slip op. at 27-28
(discussing Armstrong Surgical Ctr., Inc. v. Armstrong County Mem’l Hosp., 185 F.3d 154, 164
n.8 (3d Cir. 1999) (distinguishing case before it from cases like Walker Process and Woods
Exploration in which the governmental decision-making process relies almost solely on
information provided by petitioners); and Cheminor Drugs, Ltd. v. Ethyl Corp., 168 F.3d 119,
124 (3d Cir. 1999) (“[A] material misrepresentation that affects the very core of a litigant’s . . .
case will preclude Noerr-Pennington immunity.”)); Unocal, slip op. at 17 n.30 (citing Baltimore
Scrap Corp. v. David J. Joseph Co., 237 F.3d 394, 401-02 (4th Cir. 2001) (“If a fraud exception
to Noerr-Pennington does exist, it extends only to the type of fraud that deprives litigation of its
legitimacy.”)).
25
In its decision, the Commission confirmed that misrepresentation warrants denial of
Noerr protection outside of the political arena, provided that (1) the misrepresentation or
omission is “deliberate, factually verifiable, and central to the outcome of the proceeding or
case,” and (2) “it is possible to demonstrate and remedy this effect without undermining the
integrity of the deceived governmental entity.”
103
In reviewing the extensive case law addressing
misrepresentations, the Commission observed that federal appellate courts in nine circuits
104
have